Comparison of two selective muscarinic receptor antagonists (solifenacin and darifenacin) in women with overactive bladder--the SOLIDAR study

Scientific paper - Original scientific paper

• Title (croatian): Usporedba dva selektivna antimuskarinska lijeka (solifenacin i darifenacin) u žena s prekomjerno aktivnim mokraćnim mjehurom
• Author: Igor But
• Author: Marina Šprem Goldštajn
• Author: Slavko Orešković
• Author's institution: University of Zagreb; School of Medicine
• Scientific / art field, discipline and subdiscipline: BIOMEDICINE AND HEALTHCARE; Clinical Medical Sciences

Abstract (english)

Overactive bladder (OAB) is a common, often debilitating, condition defined as urgency and urge incontinence, usually with frequency and nocturia. The use of muscarinic receptor antagonists are the mainstay of treatment, but their non-selectivity can result in unacceptable adverse effects that limit their usefulness. The purpose of this study was to evaluate 2 of the newer antimuscarinic agents, solifenacin and darifenacin, which demonstrate greater selectivity, in order to compare their tolerance and effectiveness. This was a multicentre, prospective, randomised, comparative (1:1) open-label study conducted in 4 centres comprising Slovenian gynaecologists and urologists. A total of 77 female patients with OAB were enrolled who received either solifenacin 5 mg or darifenacin 7.5 mg once daily. Study measurements consisted of changes in OAB symptoms and quality of life (QOL) evaluations after 1 and 3 months of treatment. Both treatment groups showing a reduction in all OAB symptoms but with no notable difference being seen between the 2 groups. Solifenacin though showed statistically greater improvements in QOL, better overall treatment satisfaction, and a decreased incidence of dry mouth after 3 months of treatment compared to the darifenacin group. This study demonstrates interesting initial results and indicates that these 2 drugs have a different profile that may confer an advantage to patients, but further methodologically rigorous studies comparing the use of solifenacin and darifenacin in OAB are required to establish the differences between these drugs over longer periods of treatment.

Abstract (croatian)

Prekomjerno aktivan mokraćni mjehur (OAB) je često stanje definirano urgencijom i urgentnom inkontinencijom,
te učestalim dnevnim i noćnim mokrenjem. Terapija izbora danas je primjena antimuskarinskih lijekova. Medjutim,
ograničavajući čimbenik primjene navedenih lijekova je njihova neselektivnost što može rezultirati neželjenim učincima
i nuspojavama. Cilj ove studije je usporediti učinkovitost i podnošljivost solifenacina i darifenacina, dva novija
visokoselektivna antimuskarinska lijeka. U multicentričnu, prospektivnu, randomiziranu »open-label« studiju uključeno je 77 pacijentica s OAB-om koje su uzimale 5 mg solifenacina ili 7.5 mg darifenacina u jednokratnoj dnevnoj dozi.
Procjena učinkovitosti oba lijeka temeljila se na subjektivnoj i objektivnoj procjeni smanjenja OAB simptoma i kvalitete
života nakon mjesec i tri mjeseca liječenja. U obje ispitivane skupine dokazana je podjednaka učinkovitost u smanjenju
svih simptoma OAB-a. U skupini pacijentica koje su koristile solifenacin dokazano je statistički značajno poboljšanje
kvalitete života, bolje ukupno zadovoljstvo i smanjena učestalost suhoće ustiju nakon tri mjeseca liječenja u usporedbi
sa skupinom pacijentica koje su koristile darifenacin. Ova studija je dokazala da solifenacin i darifenacin predstavljaju
učinkovite i dobro podnošljive lijekove u liječenju OAB-a. Rezultati ove studije da primjena oba lijeka s različitim profilom
glede potencijalnih nuspojava može značajno poboljšati učinkovitost i sigurnost liječenja u pacijentica s OAB. Za
nadati se da će buduće veće, prospektivne i randomizirane kliničke studije jasnije pozicionirati učinkovitost i podnošljivost
solifenacina i darifenacina u žena s prekomjerno aktivnim mokraćnim mjehurom.

• Keywords (english): Benzofurans / administration & dosage; Benzofurans / adverse effects; Female; Humans; Middle Aged; Muscarinic Antagonists / administration & dosage; Muscarinic Antagonists / adverse effects; Prospective Studies; Pyrrolidines / administration & dosage; Pyrrolidines / adverse effects; Quality of Life; Quinuclidines / administration & dosage; Quinuclidines / adverse effects; Solifenacin Succinate; Tetrahydroisoquinolines / administration & dosage; Tetrahydroisoquinolines / adverse effects; Treatment Outcome; Urinary Bladder, Overactive / drug therapy
• Language: english
• Publication type: Scientific paper - Original scientific paper
• Publication status: Published
• Peer review: Peer review
• Publication version: Published version
• Journal title: Collegium Antropologicum
• Numbering: vol. 36, no. 4, pp. 1347-1353
• p-ISSN: 0350-6134
• URN:NBN: urn:nbn:hr:105:681564
• Publication: 2012-12
• Document URL: https://hrcak.srce.hr/94941
• Type of resource: Text
• Access conditions: Open access
• Created on: 2024-03-27 19:44:00